Biosimilars – Geographic Focus: China – Biosimilars – China In-Depth (China)
China’s biosimilar market has transformed significantly since February 2019, following the approval of Shanghai Henlius Biotech’s HLX01—a biosimilar of Roche’s MabThera (rituximab). The introduction of several cost-effective biosimilars has significantly increased the adoption of established biologics in this cost-sensitive market. Multiple key factors influence the uptake of a biosimilar in China, including price, the number of biosimilar competitors in the market, and the robustness of the clinical trials conducted by the biosimilar developer and how these data are perceived by prescribing physicians. Regulatory authorities in China are continuously working toward creating a more cohesive environment by streamlining the biosimilar development process with a focus on clinical trial design, interchangeability, and indication extrapolation. As a result of China’s evolving reforms in the biosimilar space, several companies are actively investing in the development and commercialization of emerging biosimilars in this market. Overall, we believe strong competition and continued government support will fuel significant growth in this market over the next ten years.
QUESTIONS ANSWERED
- What are interviewed experts’ opinions on the efficacy and safety of biosimilars?
- How large are China’s oncology and immunology biosimilar markets, and how will the markets evolve over the forecast period?
- Which are the most commercially relevant biosimilars being developed in the oncology and immunology spaces in China?
- What are the key market access considerations, and how are they likely to impact the uptake of emerging biosimilars in China?
PRODUCT DESCRIPTION
China In-Depth offers comprehensive market intelligence with world-class epidemiology, insight into the China-specific market access landscape, current and emerging therapies, and drug forecasts supported by detailed primary and secondary research, enabling you to:
- Optimize your long-term disease and development strategy in China.
- Quantify market potential for your pipeline assets and those of your competitors.
- Understand current treatment paradigms, the complex access and reimbursement environment, and the current and future therapeutic landscape.
RELEASE DATE
December 2025
GEOGRAPHY
China
PRIMARY RESEARCH
Country-specific qualitative and quantitative insights driven by 5 thought-leader interviews and surveys with 75 oncologists, hematologists, immunologists / rheumatologists, and gastroenterologists.
FORECAST
10-year, annualized, drug-level sales and patient share of key biologicsbrand and biosimilarsin immunology and oncology through 2034, based on primary and secondary market research to formulate bottom-up assumptions.
